|
|
|
Insider
Information: |
Heron Patrick J |
Relationship: |
Director, 10% Owner |
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
18 |
|
Direct
Shares |
33,463,806 |
|
Indirect Shares
|
27,247,271 |
|
|
Direct
Value |
$666,592,983 |
|
|
Indirect Value
|
$199,607,795 |
|
|
Total
Shares |
60,711,077 |
|
|
Total
Value |
$866,200,778 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
4
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
25.4%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Trubion Pharmaceuticals, Inc |
TRBN |
10% Owner Indirect, Di... |
|
0 |
2010-10-28 |
0 |
Premium* |
|
Cidara Therapeutics, Inc. |
CDTX |
Director |
2015-04-20 |
0 |
2015-04-20 |
291,023 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
Director |
2015-05-04 |
0 |
2015-05-04 |
2,668,570 |
Premium* |
|
Collegium Pharmaceutical, Inc |
COLL |
Director, 10% Owner |
2015-05-12 |
0 |
2015-05-12 |
1,887,332 |
Premium* |
|
Anaptysbio Inc |
ANAB |
10% Owner |
2018-05-11 |
973,612 |
2018-05-11 |
973,612 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
10% Owner |
2017-02-14 |
8,112,121 |
|
0 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2019-01-18 |
2,571,450 |
|
0 |
Premium* |
|
Aptinyx Inc. |
APTX |
10% Owner |
2018-06-25 |
3,190,079 |
2018-06-25 |
0 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
Director |
2020-07-01 |
9,006 |
2020-07-01 |
1,538,316 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
|
2019-07-22 |
0 |
2024-09-18 |
3,729,220 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
10% Owner |
2020-06-12 |
5,827,415 |
2020-06-12 |
31,446 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
10% Owner |
2020-01-09 |
1,299,953 |
2020-01-09 |
0 |
Premium* |
|
Arcutis Biotherapeutics, Inc. |
ARQT |
Director, 10% Owner |
2024-06-14 |
18,826 |
2024-03-04 |
8,808,979 |
Premium* |
|
Passage Bio, Inc. |
PASG |
Director, 10% Owner |
2020-03-03 |
0 |
2020-03-03 |
5,009,219 |
Premium* |
|
Vaxcyte, Inc. |
PCVX |
Director |
2020-06-16 |
0 |
2020-06-16 |
2,309,554 |
Premium* |
|
Tarsus Pharmaceuticals, Inc. |
TARS |
10% Owner |
2020-10-20 |
1,917,157 |
2020-10-20 |
0 |
Premium* |
|
Frazier Lifesciences Acquisition... |
FLAC |
Director |
2020-12-11 |
1,000,000 |
2020-12-11 |
0 |
Premium* |
|
Hillevax, Inc. |
HLVX |
Director, 10% Owner |
2024-04-04 |
8,544,187 |
2022-05-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
59 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TRBN |
Trubion Pharmaceuticals, ... |
Director |
|
2006-10-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,155,688 |
1,601,766 |
0 |
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
10% Owner Indirect |
|
2010-10-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,237,940) |
0 |
0 |
- |
|
CDTX |
Cidara Therapeutics, Inc. |
Director |
|
2015-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,112,258 |
291,023 |
0 |
- |
|
CDTX |
Cidara Therapeutics, Inc. |
Director |
|
2015-04-20 |
4 |
B |
$16.00 |
$3,200,000 |
I/I |
200,000 |
44,355 |
2.1 |
- |
|
TBRA |
Tobira Therapeutics Inc |
Director |
|
2015-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
2,668,570 |
2,668,570 |
0 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2015-05-12 |
4 |
B |
$12.00 |
$1,800,000 |
I/I |
150,000 |
1,887,332 |
2.25 |
- |
|
COLL |
Collegium Pharmaceutical,... |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,737,332 |
1,737,332 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
B |
$15.00 |
$4,669,365 |
D/D |
311,291 |
311,291 |
2.45 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
B |
$15.00 |
$1,330,635 |
I/I |
88,709 |
88,709 |
1.5 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
I/I |
2,437,472 |
209,095 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
733,740 |
733,740 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
B |
$15.00 |
$6,000,000 |
I/I |
400,000 |
88,709 |
1.5 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
I/I |
942,835 |
209,095 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,228,377 |
195,751 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-02-02 |
4 |
OE |
$4.55 |
$533,419 |
D/D |
117,235 |
2,345,612 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2017-02-02 |
4 |
OE |
$4.55 |
$533,419 |
I/I |
117,235 |
2,345,612 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2018-05-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,372,000) |
973,612 |
0 |
- |
|
ANAB |
Anaptysbio Inc |
10% Owner |
|
2018-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,372,000) |
973,612 |
0 |
- |
|
APTX |
Aptinyx Inc. |
10% Owner |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,040,079 |
3,040,079 |
0 |
- |
|
APTX |
Aptinyx Inc. |
10% Owner |
|
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
D/D |
150,000 |
3,190,079 |
2.45 |
- |
|
ALPN |
Alpine Immune Sciences In... |
10% Owner |
|
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
D/D |
372,439 |
2,571,450 |
2.45 |
- |
|
ITRM |
Iterum Therapeutics Plc |
Director |
|
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
6,154 |
0 |
- |
|
MIRM |
Mirum Pharmaceuticals, In... |
Director |
|
2019-07-22 |
4 |
B |
$15.00 |
$6,750,000 |
I/I |
450,000 |
3,566,912 |
2.25 |
- |
|
MIRM |
Mirum Pharmaceuticals, In... |
Director |
|
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
3,116,912 |
3,116,912 |
0 |
- |
|
ETTX |
Entasis Therapeutics Hold... |
10% Owner |
|
2020-01-09 |
4 |
S |
$5.00 |
$250,010 |
D/D |
(50,000) |
1,299,953 |
0 |
- |
|
59 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|